{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:39:37Z","timestamp":1791092377066,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1681\/asn.2009070737","type":"journal-article","created":{"date-parts":[[2009,11,19]],"date-time":"2009-11-19T22:35:14Z","timestamp":1258670114000},"page":"2641-2650","source":"Crossref","is-referenced-by-count":327,"title":["Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy"],"prefix":"10.1681","volume":"20","author":[{"given":"Uzma F.","family":"Mehdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Adams-Huet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria L.","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20230410","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1111\/j.1523-1755.2004.00988.x","article-title":"Diabetic nephropathy: Linking histology, cell biology, and genetics","volume":"66","author":"Adler","year":"2004","journal-title":"Kidney Int"},{"key":"R2-22-20230410","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"key":"R3-22-20230410","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Arch Intern Med"},{"key":"R4-22-20230410","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-22-20230410","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","article-title":"Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy","volume":"57","author":"Andersen","year":"2000","journal-title":"Kidney Int"},{"key":"R6-22-20230410","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R7-22-20230410","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"R8-22-20230410","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R9-22-20230410","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0272-6386(99)70036-3","article-title":"Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy","volume":"34","author":"Lewis","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"R10-22-20230410","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2337\/diab.42.5.715","article-title":"Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients","volume":"42","author":"Rossing","year":"1993","journal-title":"Diabetes"},{"key":"R11-22-20230410","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s001250050140","article-title":"Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment","volume":"37","author":"Rossing","year":"1994","journal-title":"Diabetologia"},{"key":"R13-22-20230410","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"R14-22-20230410","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/bmj.299.6693.230","article-title":"Prognosis in diabetic nephropathy","volume":"299","author":"Parving","year":"1989","journal-title":"BMJ"},{"key":"R15-22-20230410","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1681\/ASN.2004090763","article-title":"Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial","volume":"16","author":"Berl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R16-22-20230410","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2215\/CJN.01381005","article-title":"Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: The RENAAL study","volume":"1","author":"Keane","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R17-22-20230410","doi-asserted-by":"crossref","first-page":"F1059","DOI":"10.1152\/ajprenal.00202.2003","article-title":"Effect of aldosterone on renal transforming growth factor-\u03b2","volume":"286","author":"Juknevicius","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"R18-22-20230410","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2215\/CJN.00120106","article-title":"Aldosterone antagonism in chronic kidney disease","volume":"1","author":"Ponda","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-22-20230410","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"R20-22-20230410","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"R21-22-20230410","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R22-22-20230410","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/ndt\/gfg339","article-title":"Aldosterone receptor blockade and the role of eplerenone: Evolving perspectives","volume":"18","author":"Epstein","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R23-22-20230410","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","article-title":"Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R24-22-20230410","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"R25-22-20230410","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R26-22-20230410","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"R27-22-20230410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"R28-22-20230410","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"R29-22-20230410","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000077396","article-title":"Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME\/SHR model","volume":"24","author":"Zhou","year":"2004","journal-title":"Am J Nephrol"},{"key":"R30-22-20230410","doi-asserted-by":"crossref","first-page":"e012","DOI":"10.1621\/nrs.05012","article-title":"The mineralocorticoid receptor: Insights into its molecular and (patho)physiological biology","volume":"5","author":"Viengchareun","year":"2007","journal-title":"Nucl Recept Signal"},{"key":"R31-22-20230410","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10157-008-0034-9","article-title":"Aldosterone and glomerular podocyte injury","volume":"12","author":"Nagase","year":"2008","journal-title":"Clin Exp Nephrol"},{"key":"R32-22-20230410","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"R33-22-20230410","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R34-22-20230410","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"R35-22-20230410","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1681\/ASN.2004110919","article-title":"Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations","volume":"16","author":"Pohl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R36-22-20230410","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11906-005-0074-4","article-title":"Proteinuria reduction: Mandatory consideration or option when selecting an antihypertensive agent?","volume":"7","author":"Toto","year":"2005","journal-title":"Curr Hypertens Rep"},{"key":"R37-22-20230410","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"R39-22-20230410","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"R40-22-20230410","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1524-6175.2004.03488.x","article-title":"The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy","volume":"6","author":"Fox","year":"2004","journal-title":"J Clin Hypertens"},{"key":"R41-22-20230410","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.1985.10","article-title":"A method for estimating nitrogen intake of patients with chronic renal failure","volume":"27","author":"Maroni","year":"1985","journal-title":"Kidney Int"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-200912000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:31:59Z","timestamp":1786131119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-200912000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2009070737","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1448963.926064","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1448963.2221054","asserted-by":"object"}]},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}